Enrollment Trends Among Patients with Melanoma Brain Metastasis in Active Clinical Trials.
Cancer Invest
; 42(5): 400-407, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38773947
ABSTRACT
The CNS is a common site for distant metastasis and treatment failure in melanoma patients. This study aimed to evaluate the inclusion rate of patients with melanoma brain metastases (MBM) in prospective clinical trials. 69.3% of trials excluded MBM patients based on their CNS disease. In univariate analysis, trials not employing immunotherapy (p = 0.0174), inclusion of leptomeningeal disease (p < 0.0001) and non-pharmaceutical sponsor trials (p = 0.0461) were more likely to enroll patients with MBM. Thoughtful reconsideration of clinical trial designs is needed to give patients with MBMs access to promising investigational agents and improve outcomes for patients with MBM.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Ensaios Clínicos como Assunto
/
Seleção de Pacientes
/
Melanoma
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Invest
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos